Silver Book Fact

Omega-3 polyunsaturated fatty acids have been found to protect against the development and progression of deterioration of the retina (retinopathy).

Connor, Kip M., John P. SanGiovanni, Chatarina Lofqvist, Christopher M. Aderman, Jing Chen, Akiko Higuchi, Song Hong, Elke A. Pravda, Sharon Majchrzak, Deobrah Carper, Ann Hellstrom,Jing X. Kang, Emily Y. Chew, Norman Salem, Charles N. Sherhan, & Lois Smi. Increased Dietary Intake of Omega-3 Polyunsaturated Fatty Acids Reduces Pathological Retinal Angiogenesis. Nature Med. June 2007; 13(7): 868-73. http://www.nature.com/nm/journal/v13/n7/abs/nm1591.html

Reference

Title
Increased Dietary Intake of Omega-3 Polyunsaturated Fatty Acids Reduces Pathological Retinal Angiogenesis
Publication
Nature Med
Publication Date
June 2007
Authors
Connor, Kip M., John P. SanGiovanni, Chatarina Lofqvist, Christopher M. Aderman, Jing Chen, Akiko Higuchi, Song Hong, Elke A. Pravda, Sharon Majchrzak, Deobrah Carper, Ann Hellstrom,Jing X. Kang, Emily Y. Chew, Norman Salem, Charles N. Sherhan, & Lois Smi
Volume & Issue
Volume 13, Issue 7
Pages
868-73
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Screening and treatment for diabetic retinopathy in type 2 diabetes patients produces annual savings of 53,986 person-years of sight.  
  • Lucentis to treat wet age-related macular degeneration (AMD)
    An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25%…  
  • DR Treatment Reduced Risk of Blindness
    Appropriate treatment can reduce the risk of blindness or moderate vision loss from DR by more than 90%.  
  • The ACCORD Eye Study found that intensive glycemia control–compared with standard blood sugar control–in high risk type 2 diabetics, decreased progression of diabetic retinopathy by around 1/3 over 4 years–from…  
  • Timely treatment and follow-up care can reduce the risk of blindness in individuals with proliferative retinopathy by 95%.